

Press Note

Talent Study Gets Published in Renowned Lancet

Note on Lancet article

The study refers to the fact that India-made stents are qualitatively superior to those globally available otherwise. First time ever for an Indian medical device to be published in the Lancet, study is based on randomized controlled trials.

In medical fraternity, randomized controlled trials are considered to be of highest level of evidence, which is a significant aspect of this study and its findings. Moreover, this is the first randomized controlled trial ever conducted for a Made-in-India product.

A year after price capping of stents:

It's been a year (February 2018) that NPPA capped the prices of stents. Post that, the medical device industry has seen drastic changes, in terms of US pharma major withdrawing its stents from the markets and domestic players being seen as competition. Since then, the medical device industry has witnessed exponential growth and Indian made stents have proven to be better in TALENT study.

Recently, Cardiac drug eluting stents, designed and manufactured indigenously, have been confirmed to be at par with those manufactured globally, according to an article published in the March first week issue of the Lancet.

Make in India- medical devices:

With the Government of India focusing on 'Make in India', here are some of the sectors which can be termed as 'growth oriented' sectors. The proposed Draft National Medical Device Policy 2015 also aims at emphasizing on 'Make in India' for medical devices and strengthening the sector thus reducing the dependence on imports. India relies heavily on imported stents with majority of the sales coming from imports.

In March first week, The Lancet- the global epitome of medical journal published an article on how Indian made stents are better than the globally manufactured stents, according to TALENT study. This is the first time that the Make in India products have made to the prestigious Lancet.

With this, the Indian medical device sector is undergoing a metamorphosis and is being considered to be 'at par' in quality with the global counterparts. These developments will definitely encourage the Indian medical devices and will generate more demand for Indian coronary stents.